drugset / Trial / NCT03720223

Liposomal Bupivacaine To Control Post-Operative Pain Following BMG

NCT03720223

Phase 3 Completed 50 enrolled Urology of Virginia
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a single blinded-randomized controlled trial that recruit male patients for substitution urethroplasty using buccal mucosal graft. The study investigators aim to assess the efficacy and safety of liposomal bupivacaine injection to the buccal graft harvest site on post-operative main score, morphine equivalence requirement and oral morbidities.

Timeline

Start
2015-01-20
Primary completion
2017-10-31
Completion
2017-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 1.3 % Other
Subject Bupivacaine Other / unclassified 13.3 mg/ml Other
Subject Bupivacaine Other / unclassified 20 ml Other

Indications